Company Overview of Enumeral Biomedical Corp.

Company Overview

Enumeral Biomedical Corp. engages in the discovery and development of native human monoclonal antibodies for use in the diagnosis and treatment of infectious, autoimmune, and inflammatory diseases, and cancers. It uses its proprietary microengraving technology that creates high-density bio-chip microarrays of the secreted products of single human cells derived from patient samples to provide analysis of antibody affinity and specificity, as well as cytokine profiles and T-cell functionality. The company was formerly known as Enumeral Technologies, Inc., and changed its name to Enumeral Biomedical Corp. in November 2010. Enumeral Biomedical Corp. was founded in 2009 and is based in New York, ...

Enumeral Biomedical Corp. engages in the discovery and development of native human monoclonal antibodies for use in the diagnosis and treatment of infectious, autoimmune, and inflammatory diseases, and cancers. It uses its proprietary microengraving technology that creates high-density bio-chip microarrays of the secreted products of single human cells derived from patient samples to provide analysis of antibody affinity and specificity, as well as cytokine profiles and T-cell functionality. The company was formerly known as Enumeral Technologies, Inc., and changed its name to Enumeral Biomedical Corp. in November 2010. Enumeral Biomedical Corp. was founded in 2009 and is based in New York, New York. It has a research laboratory in Cambridge, Massachusetts.

Key Executives for Enumeral Biomedical Corp.

Similar Private Companies By Industry

Recent Private Companies Transactions